Letters sent to healthcare professionals in May 2016

In May 2016, letters were sent regarding Nexplanon (etonogestrel implant) and ERWINASE.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 15 June 2016

• Therapeutic area: Cancer and Obstetrics, gynaecology and fertility

In May 2016, letters were sent regarding:

• Nexplanon (etonogestrel) implants have been found rarely in the vasculature and lung: an update regarding possible risks and complications regarding insertion, localisation and removal (Nexplanon letter to healthcare professionals May 2016)—see also article in this issue

• ERWINASE: notice of special handling instructions—vials of ERWINASE from batch 174g should be used with a 5-micron filter needle (ERWINASE letter to healthcare professionals May 2016)

Article citation: Drug Safety Update vol 9 issue 11, June 2016: 4.

Published 15 June 2016